ENZ - Enzo Biochem Inc Stock Price, Fair Value and News

1.07USD-0.02 (-1.83%)Market Closed

Market Summary

USD1.07-0.02

Market Closed

-1.83%

ENZ Stock Price

View Fullscreen

ENZ RSI Chart

ENZ Valuation

Market Cap

55.8M

Price/Earnings (Trailing)

1.71

Price/Sales (Trailing)

1.7

EV/EBITDA

0.26

Price/Free Cashflow

-1.26

ENZ Price/Sales (Trailing)

ENZ Profitability

Operating Margin

78.45%

EBT Margin

-50.18%

Return on Equity

46.01%

Return on Assets

32.87%

Free Cashflow Yield

-79.51%

ENZ Fundamentals

ENZ Revenue

Revenue (TTM)

32.8M

Rev. Growth (Yr)

13.83%

Rev. Growth (Qtr)

9.57%

ENZ Earnings

Earnings (TTM)

32.6M

Earnings Growth (Yr)

72.96%

Earnings Growth (Qtr)

53.73%

Breaking Down ENZ Revenue

Last 7 days

-5.2%

Last 30 days

-13.5%

Last 90 days

-16.2%

Trailing 12 Months

-57.1%

How does ENZ drawdown profile look like?

ENZ Financial Health

Current Ratio

3.2

Debt/Equity

Debt/Cashflow

-189.73

ENZ Investor Care

Shares Dilution (1Y)

5.11%

Diluted EPS (TTM)

0.67

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	32.8M	0	0	0
2023	31.9M	31.5M	31.1M	31.8M
2022	118.2M	111.6M	32.6M	32.2M
2021	96.6M	112.4M	117.7M	115.6M
2020	78.6M	77.3M	76.0M	84.5M
2019	88.6M	83.0M	81.2M	79.9M
2018	103.1M	102.1M	101.0M	95.4M
2017	105.6M	106.2M	105.2M	104.1M
2016	99.4M	101.9M	102.8M	103.9M
2015	96.8M	96.8M	97.6M	98.0M
2014	92.9M	94.3M	95.9M	96.6M
2013	100.2M	96.8M	93.7M	92.2M
2012	103.4M	103.5M	103.1M	103.0M
2011	99.6M	100.8M	102.0M	102.1M
2010	0	0	97.1M	98.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Enzo Biochem Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 23, 2024	cannon kara	acquired	-	-	150,000	chief executive officer
Feb 21, 2024	cannon kara	sold (taxes)	-	-	-5,823	chief executive officer
Feb 21, 2024	cannon kara	acquired	-	-	10,640	chief executive officer
Jan 31, 2024	tagliaferri mary	acquired	-	-	79,365	-
Jan 31, 2024	radoff bradley louis	acquired	-	-	79,365	-
Jan 31, 2024	pully steven j	acquired	-	-	79,365	-
Oct 30, 2023	pully steven j	acquired	-	-	17,730	-
Aug 31, 2023	cannon kara	acquired	-	-	345,080	chief operating officer
Aug 31, 2023	cannon kara	sold (taxes)	-98,098	1.54	-63,700	chief operating officer
Feb 13, 2023	wolf james g.	bought	6,425	1.285	5,000	-

Which funds bought or sold ENZ recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Sage Mountain Advisors LLC	unchanged	-	-1,703	18,028	-%
Apr 23, 2024	BFSG, LLC	new	-	3,573	3,573	-%
Apr 22, 2024	PFG Investments, LLC	new	-	23,701	23,701	-%
Apr 16, 2024	Shulman DeMeo Asset Management LLC	unchanged	-	-1,859	19,668	-%
Apr 15, 2024	Sound Income Strategies, LLC	new	-	13.00	13.00	-%
Apr 11, 2024	KEMPNER CAPITAL MANAGEMENT INC.	unchanged	-	-3,000	32,000	0.02%
Mar 11, 2024	VANGUARD GROUP INC	added	8.53	187,786	2,608,500	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	unchanged	-	-	63,000	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	16,068	16,068	-%
Feb 15, 2024	Potomac Capital Management, Inc.	added	1.84	22,621	2,059,620	2.39%

Are Funds Buying or Selling ENZ?

Are funds buying ENZ calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ENZ

No. of Funds

Unveiling Enzo Biochem Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	1 main capital management, llc	4.95%	2,500,000	SC 13G/A
Feb 13, 2024	renaissance technologies llc	4.91%	2,479,195	SC 13G/A
Sep 11, 2023	1 main capital management, llc	5.8%	2,874,125	SC 13G
Jul 24, 2023	laboratory corp of america holdings	0%	0	SC 13D/A
May 10, 2023	radoff bradley louis	9.3%	430,000	SC 13D/A
Mar 27, 2023	laboratory corp of america holdings	9.8%	4,862,730	SC 13D
Feb 13, 2023	renaissance technologies llc	5.78%	2,813,964	SC 13G/A
Jan 23, 2023	wolf james g.	10.14%	0	SC 13D/A
Nov 23, 2022	wolf james g.	8.56%	4,168,500	SC 13D/A
Oct 26, 2022	wolf james g.	8.45%	4,114,500	SC 13D/A

Recent SEC filings of Enzo Biochem Inc

View All Filings

Date Filed	Form Type	Document
Mar 13, 2024	8-K	Current Report
Mar 13, 2024	10-Q	Quarterly Report
Feb 27, 2024	8-K	Current Report
Feb 27, 2024	4	Insider Trading
Feb 27, 2024	4	Insider Trading
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 02, 2024	4	Insider Trading
Feb 02, 2024	4	Insider Trading
Feb 02, 2024	4	Insider Trading

Peers (Alternatives to Enzo Biochem Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	174.4B	23.7B	-0.66%	-0.48%	39.62	7.35	-8.94%	-35.72%
IDXX	41.0B	3.7B	-6.96%	-1.95%	48.55	11.21	8.72%	24.44%
A	40.8B	6.7B	-5.62%	0.50%	33	6.06	-2.81%	-6.58%
DGX	15.1B	9.3B	5.76%	-6.69%	17.73	1.64	-6.38%	-9.73%
CRL	12.3B	4.1B	-11.91%	17.80%	25.98	2.99	3.86%	-2.39%
EXAS	11.5B	2.5B	2.30%	-4.05%	-56.49	4.61	19.93%	67.26%
MEDP	11.5B	2.0B	-0.40%	117.42%	36.88	5.87	25.57%	21.62%
NTRA	11.0B	1.1B	-1.39%	71.77%	-25.28	10.16	31.99%	20.63%
MID-CAP
NEOG	2.7B	929.2M	-19.07%	-29.09%	1.7K	2.87	28.93%	111.61%
GH	2.1B	563.9M	0.58%	-24.79%	-4.4	3.74	25.45%	26.76%
SMALL-CAP
CDNA	426.1M	280.3M	-13.73%	-2.49%	-2.24	1.52	-12.89%	-148.37%
ACRS	86.5M	31.2M	6.09%	-86.56%	-0.98	2.77	5.03%	-1.81%
AWH	41.8M	9.2M	-7.12%	-37.22%	-2.51	4.57	11.85%	44.12%
APDN	4.9M	9.0M	-42.00%	-72.12%	-0.68	0.55	-53.31%	2.21%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Enzo Biochem Inc News

Latest updates

Enzo Biochem Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q3	2019Q2
Revenue	9.6%	8,553,000	7,806,000	337,000	16,107,000	7,514,000	7,103,000	16,662,500	26,222,000	34,046,000	26,519,000	24,813,000	32,797,000	31,466,000	28,655,000	19,527,000	16,903,000	19,384,000	20,207,000	20,564,000	20,921,000	19,662,000
Cost Of Revenue	-0.5%	4,329,000	4,351,000	-16,080,500	14,469,000	4,616,000	4,589,000	-29,947,000	16,049,000	17,838,000	15,273,000	-	-	-	-	-	-	-	-	-	-	-
Costs and Expenses	-	-	-	-	-	-	-	-	29,358,000	35,969,000	28,351,000	-	30,730,000	29,756,000	28,158,000	23,958,000	26,627,000	27,393,000	28,410,000	-	26,586,000	-2,607,000
Operating Expenses	-	10,738,000	-	-	-	12,059,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	-27.7%	5,068,000	7,007,000	-1,885,000	12,022,000	5,430,000	5,437,000	-13,876,000	11,442,000	14,466,000	11,052,000	11,796,000	12,082,000	11,013,000	10,014,000	10,067,000	11,061,000	10,693,000	11,139,000	-	10,878,000	10,920,000
R&D Expenses	-31.7%	580,000	849,000	803,500	975,000	1,125,000	699,000	-259,000	1,133,000	820,000	744,000	864,000	836,000	806,000	746,000	1,166,000	1,163,000	1,065,000	1,054,000	-	833,000	781,000
EBITDA Margin	7.1%	-0.50	-0.54	-0.58	-1.26	-0.94	-0.67	-0.34	0.01	0.08	0.08	0.07	-0.06	-	-	-	-	-	-	-	-	-
Interest Expenses	8.6%	-893,000	-977,000	1,160,500	-37,000	-63,000	-72,000	-347,500	54,000	68,000	56,000	277,000	60,000	-49,000	-51,000	-229,000	87,000	171,000	237,000	-	-	258,000
Income Taxes	-	-	-	-	-	-	-	-	-	-	29,000	-	-	-	22,000	-	-	-	43,000	-	-	-
Earnings Before Taxes	84.8%	-863,000	-5,675,000	5,265,500	-15,187,000	-2,892,000	-5,354,000	-10,511,000	-4,854,000	-2,655,000	-	5,080,000	2,006,000	2,302,000	-	-3,325,000	-9,860,000	-7,687,000	-7,648,000	-	-5,390,000	22,265,000
EBT Margin	13.8%	-0.50	-0.58	-0.72	-1.35	-1.01	-0.72	-0.40	0.00	0.06	0.05	0.05	-0.08	-	-	-	-	-	-	-	-	-
Net Income	53.7%	-3,061,000	-6,616,000	57,430,000	-15,187,000	-11,320,000	-10,635,000	-8,433,000	-4,854,000	-2,655,000	-2,319,000	3,268,000	2,006,000	2,302,000	299,000	-3,325,000	-9,890,000	-7,687,000	-7,648,000	-	-5,390,000	22,265,000
Net Income Margin	29.7%	0.99	0.77	0.65	-1.45	-1.11	-0.82	-0.56	-0.06	0.00	0.05	0.07	0.01	-	-	-	-	-	-	-	-	-
Free Cashflow	33.2%	-8,938,000	-13,374,000	-17,887,000	-5,910,000	-7,054,000	-9,549,000	-9,926,000	-1,703,000	-1,844,000	-7,076,000	-1,458,000	560,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-6.8%	99.00	106	122	72.00	76.00	85.00	76.00	104	109	108	114	114	112	114	113	116	117	125	107	111	89.00
Current Assets	-8.1%	81.00	88.00	98.00	32.00	36.00	45.00	43.00	62.00	67.00	66.00	71.00	71.00	70.00	70.00	69.00	72.00	71.00	77.00	81.00	86.00	64.00
Cash Equivalents	-13.0%	60.00	69.00	82.00	3.00	5.00	12.00	23.00	31.00	4.00	6.00	14.00	15.00	45.00	46.00	48.00	54.00	52.00	57.00	61.00	64.00	42.00
Inventory	2.7%	8.00	8.00	8.00	15.00	16.00	16.00	10.00	15.00	14.00	0.00	13.00	11.00	9.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00
Net PPE	-1.8%	13.00	13.00	13.00	18.00	17.00	17.00	12.00	18.00	18.00	17.00	17.00	16.00	14.00	15.00	14.00	13.00	14.00	14.00	14.00	14.00	14.00
Goodwill	-	-	-	-	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00
Liabilities	-11.6%	28.00	32.00	43.00	53.00	44.00	40.00	21.00	42.00	44.00	41.00	45.00	49.00	50.00	54.00	54.00	54.00	46.00	47.00	21.00	20.00	22.00
Current Liabilities	-12.3%	25.00	29.00	40.00	42.00	32.00	24.00	13.00	25.00	26.00	23.00	26.00	29.00	30.00	34.00	33.00	32.00	23.00	23.00	16.00	15.00	17.00
Long Term Debt	6.8%	0.00	0.00	0.00	0.00	0.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	5.00	4.00	4.00	4.00	-	-
LT Debt, Current	13.5%	3.00	3.00	3.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	6.8%	0.00	0.00	0.00	0.00	0.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	5.00	4.00	4.00	4.00	-	-
Shareholder's Equity	-4.7%	71.00	74.00	78.00	19.00	33.00	45.00	54.00	62.00	65.00	67.00	69.00	65.00	62.00	59.00	58.00	62.00	71.00	78.00	86.00	91.00	67.00
Retained Earnings	-1.1%	-278	-274	-268	-325	-310	-299	-288	-280	-275	-272	-270	-273	-275	-277	-278	-274	-265	-257	-249	-244	-266
Additional Paid-In Capital	0.1%	346	346	344	342	340	340	339	339	338	337	337	337	336	335	334	334	333	333	333	332	331
Shares Outstanding	0%	50.00	50.00	50.00	50.00	49.00	49.00	49.00	49.00	48.00	48.00	48.00	48.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	56.00	-	-	-	132	-	-	-	132	-	-	-	110	-	-	-	164

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	33.2%	-8,938	-13,374	-17,031	-5,054	-6,198	-8,693	-9,070	-847	-630	-6,043	108	2,307	-820	-1,208	-5,061	-4,127	-5,925	-2,066	-3,175	22,756	-8,571
Share Based Compensation	-75.7%	261	1,075	760	563	515	430	439	162	679	216	267	297	176	167	205	207	302	219	214	199	291
Cashflow From Investing	90.2%	-25.00	-254	101,167	-666	-869	-652	-369	27,894	-1,241	-1,061	-1,604	-31,770	-506	-617	-1,451	-285	-160	-274	-572	-566	-5,973
Cashflow From Financing	95.8%	-22.00	-518	-4,240	3,272	-62.00	-95.00	-96.00	-31.00	-57.00	-57.00	-56.00	21.00	-94.00	-113	-90.00	7,320	-58.00	-171	-157	-106	4,490

ENZ Income Statement

2024-01-31

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2024	Jan. 31, 2023
Income Statement [Abstract]
Revenues	$ 8,553	$ 7,514	$ 16,359	$ 14,617
Operating costs and expenses:
Cost of revenues	4,329	4,616	8,680	9,205
Research and development	580	1,125	1,429	1,824
Selling, general and administrative	5,068	5,430	12,070	10,866
Legal and related expense, net	761	888	1,835	1,895
Total operating costs and expenses	10,738	12,059	24,014	23,790
Operating loss	(2,185)	(4,545)	(7,655)	(9,173)
Other income (expense):
Interest, net	893	63	1,870	135
Change in fair value of convertible debentures	(383)		(711)
Other	119	118	276	118
Foreign exchange gain (loss)	693	1,472	(318)	675
Total other income (expense)	1,322	1,653	1,117	928
Loss before income taxes	(863)	(2,892)	(6,538)	(8,245)
Income taxes
Net loss from continuing operations	(863)	(2,892)	(6,538)	(8,245)
Net loss from discontinued operations	(2,198)	(8,428)	(3,139)	(13,710)
Net loss	$ (3,061)	$ (11,320)	$ (9,677)	$ (21,955)
Net loss per common share – basic and diluted:
Continuing operations (in Dollars per share)	$ (0.02)	$ (0.06)	$ (0.13)	$ (0.17)
Discontinued operations (in Dollars per share)	(0.04)	(0.17)	(0.06)	(0.28)
Total net loss per basic and diluted common share (in Dollars per share)	$ (0.06)	$ (0.23)	$ (0.19)	$ (0.45)
Weighted average common shares outstanding:
Basic (in Shares)	50,490	48,729	50,337	48,725

ENZ Balance Sheet

2024-01-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Jan. 31, 2024	Jul. 31, 2023
Current assets:
Cash and cash equivalents	$ 60,241	$ 82,373
Accounts receivable, net	5,116	4,808
Inventories, net	7,800	7,939
Prepaid expenses and other current assets, including $5,000 escrow at January 31, 2024 and $1,000 restricted cash at July 31, 2023	7,763	3,336
Total current assets	80,920	98,456
Property, plant, and equipment, net	12,837	13,086
Right-of-use assets	3,187	3,626
Other assets, including $5,000 escrow at July 31, 2023	645	5,745
Non-current assets of discontinued operations, net	1,488	967
Total assets	99,077	121,880
Current liabilities:
Accounts payable – trade	1,318	3,575
Accrued liabilities	7,526	11,743
Current portion of operating lease liabilities	862	980
Other current liabilities	75	75
Convertible debentures	3,225	2,514
Current liabilities of discontinued operations, net	12,277	21,102
Total current liabilities	25,283	39,989
Operating lease liabilities, non-current	2,785	3,160
Long term debt, net	234	269
Total liabilities	28,302	43,418
Contingencies – see Note 13
Stockholders’ equity:
Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding
Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 50,489,771 at January 31, 2024 and 49,997,631 at July 31, 2023	504	499
Additional paid-in capital	346,252	344,435
Accumulated deficit	(278,027)	(268,350)
Accumulated other comprehensive income	2,046	1,878
Total stockholders’ equity	70,775	78,462
Total liabilities and stockholders’ equity	$ 99,077	$ 121,880

About Enzo Biochem Inc

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing Ã‚â€˜STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in Farmingdale, New York.

CEO	Ms. Kara Cannon
WEBSITE	enzo.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	465

Enzo Biochem Inc Frequently Asked Questions

What is the ticker symbol for Enzo Biochem Inc? What does ENZ stand for in stocks?

ENZ is the stock ticker symbol of Enzo Biochem Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Enzo Biochem Inc (ENZ)?

As of Tue Apr 23 2024, market cap of Enzo Biochem Inc is 55.84 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ENZ stock?

You can check ENZ's fair value in chart for subscribers.

What is the fair value of ENZ stock?

You can check ENZ's fair value in chart for subscribers. The fair value of Enzo Biochem Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Enzo Biochem Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ENZ so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Enzo Biochem Inc a good stock to buy?

The fair value guage provides a quick view whether ENZ is over valued or under valued. Whether Enzo Biochem Inc is cheap or expensive depends on the assumptions which impact Enzo Biochem Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ENZ.

What is Enzo Biochem Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, ENZ's PE ratio (Price to Earnings) is 1.71 and Price to Sales (PS) ratio is 1.7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ENZ PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Enzo Biochem Inc's stock?

In the past 10 years, Enzo Biochem Inc has provided -0.128 (multiply by 100 for percentage) rate of return.